NO2718426T3 - - Google Patents
Info
- Publication number
- NO2718426T3 NO2718426T3 NO12732995A NO12732995A NO2718426T3 NO 2718426 T3 NO2718426 T3 NO 2718426T3 NO 12732995 A NO12732995 A NO 12732995A NO 12732995 A NO12732995 A NO 12732995A NO 2718426 T3 NO2718426 T3 NO 2718426T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11169655 | 2011-06-11 | ||
EP11177524A EP2532740A1 (en) | 2011-06-11 | 2011-08-12 | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
PCT/EP2012/061041 WO2012171882A1 (en) | 2011-06-11 | 2012-06-11 | Antigen-specific central-memory t cell preparations having high cd4+ fraction |
EP12732995.1A EP2718426B1 (en) | 2011-06-11 | 2012-06-11 | Antigen-specific central-memory t cell preparations having high cd4+ fraction |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2718426T3 true NO2718426T3 (en) | 2018-04-21 |
Family
ID=45998693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO12732995A NO2718426T3 (en) | 2011-06-11 | 2012-06-11 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9763985B2 (en) |
EP (2) | EP2532740A1 (en) |
DE (1) | DE112012002430T5 (en) |
DK (1) | DK2718426T3 (en) |
ES (1) | ES2659756T3 (en) |
NO (1) | NO2718426T3 (en) |
WO (1) | WO2012171882A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
JP2017528433A (en) * | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | Low immunoenhancing dose of mTOR inhibitor and CAR combination |
BR112017005631A2 (en) * | 2014-09-19 | 2018-06-26 | City Of Hope | il13ra2-targeted chimeric costimulator antigen receptor t cells |
KR20230148387A (en) | 2015-05-28 | 2023-10-24 | 카이트 파마 인코포레이티드 | Diagnostic methods for t cell therapy |
IL305621A (en) | 2015-05-28 | 2023-11-01 | Us Health | Methods of conditioning patients for t cell therapy |
SG11201802966TA (en) | 2015-10-20 | 2018-05-30 | Kite Pharma Inc | Methods of preparing t cells for t cell therapy |
WO2017173384A1 (en) | 2016-04-01 | 2017-10-05 | Kite Pharma, Inc. | Chimeric receptors and methods of use thereof |
SI3436079T1 (en) | 2016-04-01 | 2022-01-31 | Kite Pharma, Inc. | Chimeric antigen and t cell receptors and methods of use |
CN109414455B (en) | 2016-04-01 | 2023-01-20 | 凯德药业股份有限公司 | BCMA binding molecules and methods of use thereof |
AU2018219862B2 (en) | 2017-02-07 | 2020-09-17 | Nant Holding IP, LLC | Maximizing T-cell memory and compositions and methods therefor |
US11046775B2 (en) | 2017-02-14 | 2021-06-29 | Kite Pharma, Inc. | CD70 binding molecules and methods of use thereof |
WO2018169922A2 (en) | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
MX2019011679A (en) | 2017-04-01 | 2019-11-01 | Avm Biotechnology Llc | Replacement of cytotoxic preconditioning before cellular immunotherapy. |
CA3057880A1 (en) | 2017-04-03 | 2018-10-11 | Kite Pharma, Inc. | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells |
JOP20180042A1 (en) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | Humanized Antigen-Binding Domains and Methods of Use |
KR20230143631A (en) | 2017-05-26 | 2023-10-12 | 카이트 파마 인코포레이티드 | Methods of making and using embryonic mesenchymal progenitor cells |
KR20230052312A (en) | 2017-09-15 | 2023-04-19 | 카이트 파마 인코포레이티드 | Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking |
SG11202002533QA (en) | 2017-09-22 | 2020-04-29 | Kite Pharma Inc | Chimeric polypeptides and uses thereof |
KR20230011487A (en) | 2017-10-18 | 2023-01-20 | 카이트 파마 인코포레이티드 | Methods of administering chimeric antigen receptor immunotherapy |
WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
CN111867680A (en) | 2018-01-15 | 2020-10-30 | 辉瑞大药厂 | Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1BB agonists |
US20200390814A1 (en) | 2018-02-02 | 2020-12-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna-chimeric antigen receptor t cells for immunotherapy |
JP2021513839A (en) | 2018-02-16 | 2021-06-03 | カイト ファーマ インコーポレイテッドKite Pharma, Inc | Modified pluripotent stem cells and manufacturing method and usage method |
IL310416A (en) | 2018-04-12 | 2024-03-01 | Kite Pharma Inc | Chimeric receptor t cell treatment using characteristics of the tumor microenvironment |
WO2019232510A1 (en) | 2018-06-01 | 2019-12-05 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
US20210155941A1 (en) | 2018-06-22 | 2021-05-27 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
EP3830125A1 (en) | 2018-08-02 | 2021-06-09 | Kite Pharma, Inc. | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
MX2021005372A (en) | 2018-11-08 | 2021-09-14 | Neximmune Inc | T cell compositions with improved phenotypic properties. |
WO2020102701A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Methods for the manufacture of th1/tc1 phenotype t cells |
WO2020102708A1 (en) | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Methods for treating cancer with manufactured t cells |
WO2020102715A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Method for t cell de-differentiation and resulting cells |
BR112021012172A2 (en) | 2018-12-12 | 2021-08-31 | Kite Pharma, Inc. | CHIMERIC AND T-CELL ANTIGEN RECEPTORS AND METHODS OF USE |
US20200384027A1 (en) | 2019-05-03 | 2020-12-10 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
EP3976068A4 (en) * | 2019-05-31 | 2023-08-09 | Children's National Medical Center | Cytokine cocktails for selective expansion of t cell subsets |
JP2022536975A (en) | 2019-06-21 | 2022-08-22 | カイト ファーマ インコーポレイテッド | TGF-β RECEPTOR AND METHOD OF USE |
US11160832B2 (en) | 2019-07-09 | 2021-11-02 | The Children's Mercy Hospital | Engineered regulatory T cells |
KR20220054383A (en) | 2019-09-03 | 2022-05-02 | 알로젠 테라퓨틱스 인코포레이티드 | Methods of making T cells for T cell therapy |
US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
EP3957720A1 (en) | 2020-08-21 | 2022-02-23 | Charité - Universitätsmedizin Berlin | Immunosuppressant-resistant t-cells for adoptive immunotherapy |
CA3191161A1 (en) | 2020-08-14 | 2022-02-17 | Kite Pharma, Inc | Improving immune cell function |
EP4204545A2 (en) | 2020-08-25 | 2023-07-05 | Kite Pharma, Inc. | T cells with improved functionality |
WO2022093925A1 (en) | 2020-10-28 | 2022-05-05 | Kite Pharma, Inc. | Flow cytometric method for characterization of t-cell impurities |
AU2021410635A1 (en) | 2020-12-24 | 2023-06-29 | Kite Pharma, Inc. | Prostate cancer chimeric antigen receptors |
CA3207182A1 (en) | 2021-01-10 | 2022-07-14 | Kite Pharma, Inc. | T cell therapy |
TW202241469A (en) | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | Immunotherapies |
WO2022192439A1 (en) | 2021-03-11 | 2022-09-15 | Kite Pharma, Inc. | Improving immune cell function |
US20220336087A1 (en) | 2021-04-16 | 2022-10-20 | Kite Pharma, Inc. | Methods and systems for scheduling a patient-specific immunotherapy procedure |
IL307384A (en) | 2021-04-16 | 2023-11-01 | Kite Pharma Inc | Taci/bcma dual binding molecules |
IL308227A (en) | 2021-05-14 | 2024-01-01 | Kite Pharma Inc | Chimeric antigen receptor t cell therapy |
WO2022251120A2 (en) | 2021-05-24 | 2022-12-01 | Kite Pharma, Inc. | Chimeric antigen receptor |
CN117730100A (en) | 2021-06-08 | 2024-03-19 | 凯德药业股份有限公司 | GPC3 binding molecules |
WO2023278553A1 (en) | 2021-07-01 | 2023-01-05 | Kite Pharma, Inc. | Closed-system and method for autologous and allogeneic cell therapy manufacturing |
WO2023278619A1 (en) | 2021-07-02 | 2023-01-05 | Kite Pharma, Inc. | A method for identifying variants in gene products from gene constructs used in cell therapy applications |
US20230060292A1 (en) | 2021-07-26 | 2023-03-02 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
WO2023010114A1 (en) | 2021-07-30 | 2023-02-02 | Kite Pharma, Inc. | Monitoring and management of cell therapy-induced toxicities |
CA3232254A1 (en) | 2021-10-18 | 2023-04-27 | Kite Pharma, Inc. | Signaling domains for chimeric antigen receptors |
US20230296610A1 (en) | 2022-02-15 | 2023-09-21 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
US20240091261A1 (en) | 2022-08-26 | 2024-03-21 | Kite Pharma, Inc. | Immune cell function |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US551413A (en) | 1895-12-17 | Willakd b | ||
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
US5023264A (en) | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
US5023263A (en) | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
US5130307A (en) | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
US5221670A (en) | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
US5233036A (en) | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
JP3210095B2 (en) | 1992-10-13 | 2001-09-17 | ハッコールケミカル株式会社 | Organic white pigment |
US5302584A (en) | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
US5480989A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
US5480988A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5411967A (en) | 1992-10-13 | 1995-05-02 | American Home Products Corporation | Carbamates of rapamycin |
US5262423A (en) | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
US5504091A (en) | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
US5378836A (en) | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
US5391730A (en) | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
US5373014A (en) | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
US5385910A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
US5385909A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
US5389639A (en) | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5463048A (en) | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
US5491231A (en) | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
US5563145A (en) | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
DE10009341A1 (en) | 2000-02-22 | 2001-09-06 | Florian Kern | Method for antigen-specific stimulation of T lymphocytes |
US20100254958A1 (en) | 2007-10-24 | 2010-10-07 | Anne Letsch | Antigen-Specific T-Cell Preparations from Bone Marrow |
US9057054B2 (en) * | 2009-06-25 | 2015-06-16 | The Regents Of The University Of Michigan | Antigen-specific long-term memory T-cells |
-
2011
- 2011-08-12 EP EP11177524A patent/EP2532740A1/en not_active Withdrawn
-
2012
- 2012-06-11 DK DK12732995.1T patent/DK2718426T3/en active
- 2012-06-11 ES ES12732995.1T patent/ES2659756T3/en active Active
- 2012-06-11 EP EP12732995.1A patent/EP2718426B1/en active Active
- 2012-06-11 US US14/125,101 patent/US9763985B2/en not_active Expired - Fee Related
- 2012-06-11 NO NO12732995A patent/NO2718426T3/no unknown
- 2012-06-11 WO PCT/EP2012/061041 patent/WO2012171882A1/en active Application Filing
- 2012-06-11 DE DE112012002430.3T patent/DE112012002430T5/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2012171882A1 (en) | 2012-12-20 |
EP2532740A1 (en) | 2012-12-12 |
ES2659756T3 (en) | 2018-03-19 |
DK2718426T3 (en) | 2018-02-26 |
EP2718426A1 (en) | 2014-04-16 |
DE112012002430T5 (en) | 2014-03-06 |
EP2718426B1 (en) | 2017-11-22 |
US20140154228A1 (en) | 2014-06-05 |
US9763985B2 (en) | 2017-09-19 |